{"url_path":"/sec/mira/8-k/2026-05-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-022608-index.html","accession_number":"0001493152-26-022608","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-022608-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":361,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events**\n\n \n\nOn\nMay 13, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) announced the publication of a peer-reviewed manuscript relating\nto SKNY-1, the Company’s investigational oral drug candidate being evaluated for obesity and nicotine addiction, in the *International\nJournal of Molecular Sciences*.\n\n \n\nThe\nmanuscript, titled *“SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors\nin an mc4r(G894C) Zebrafish Model of Obesity,”* describes preclinical in vitro pharmacologic characterization and in vivo findings\nobserved in an MC4R-deficient zebrafish model exhibiting obesity-associated metabolic and reward-related phenotypes.\n\n \n\nAccording\nto the publication, SKNY-1 demonstrated differential engagement of cannabinoid receptor 1 (CB1) signaling pathways, partial agonist activity\nat cannabinoid receptor 2 (CB2), and selective in vitro inhibition of monoamine oxidase B (MAO-B) relative to MAO-A.\n\n \n\nThe\npublication further reports that oral administration of SKNY-1 in the evaluated preclinical model was associated with dose-dependent\nreductions in body weight following six days of treatment, including approximately 30% reduction relative to baseline in the higher-dose\ngroup. The manuscript also reports no significant reduction in whole-body density during the treatment period.\n\n \n\nAdditional\nfindings described in the publication include normalization of total cholesterol and low-density lipoprotein (LDL) levels, increased\nhigh-density lipoprotein (HDL) levels, reduction of hepatic triglyceride accumulation, modulation of leptin and ghrelin gene expression\npatterns, and attenuation of compulsive feeding and nicotine-seeking behaviors in multiple behavioral paradigms.\n\n \n\nThe\nCompany previously reported additional preclinical behavioral findings consistent with SKNY-1’s differentiated CB1 pathway engagement,\nincluding attenuation of anxiety-like behaviors in a validated zebrafish behavioral model evaluating cannabinoid-related central nervous\nsystem effects.\n\n \n\nThe\npublication is available online through MDPI at https://www.mdpi.com/1422-0067/27/10/4321.\n\n \n\nThe\nfindings described in the publication are based on preclinical research conducted in zebrafish models and in vitro systems. SKNY-1 has\nnot been approved by the U.S. Food and Drug Administration (“FDA”) for any indication, and the safety and efficacy of SKNY-1\nhave not been established in humans.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**MIRA\nPHARMACEUTICALS, INC.**\n\n \n \n\nDated:\nMay 13, 2026\nBy:\n*/s/\nErez Aminov*\n\n \nName:\nErez\nAminov\n\n \nTitle:\nChief\nExecutive Officer"}